Levobupivacaína Altan (Levobupivacaine)

Levobupivacaine works by reversibly binding to the intracellular portion of voltage‑gated sodium channels on neuronal membranes. This stabilizes the channel in its inactive state, blocking sodium influx and preventing the initiation and propagation of nerve impulses. The resulting interruption of signal transmission produces localized loss of sensation and pain relief without affecting consciousness.

The appropriate dose of Levobupivacaína Altan is determined by the prescribing clinician based on the specific procedure, patient characteristics, and the intended route of administration (epidural, infiltration, intrathecal or peripheral nerve block). Dosage calculations consider factors such as age, weight, comorbidities and the desired depth and duration of anesthesia.

Safety data for levobupivacaine during pregnancy and lactation are limited. It may be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and only under close medical supervision. Breastfeeding mothers should consult their healthcare provider, as the drug can be excreted in small amounts in breast milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and the necessary import documentation.

Levobupivacaína Altan is the S‑enantiomer of bupivacaine, offering a similar duration of anesthesia with a lower risk of cardiotoxicity and central nervous system toxicity. While both agents provide effective nerve block, levobupivacaine’s improved safety profile makes it preferable in patients with cardiovascular concerns or when higher doses are required for prolonged procedures.

Levobupivacaína Altan should be stored at room temperature, below 25 °C, in its original sealed container. Protect the product from direct sunlight, moisture and extreme temperature fluctuations. Before use, inspect the solution for any particulate matter or discoloration, and handle it with aseptic technique to maintain sterility.

Levobupivacaína Altan is administered by a qualified healthcare professional via epidural, infiltration, intrathecal or peripheral nerve block techniques. The drug is supplied as a sterile solution that is injected directly into the target tissue or space under aseptic conditions. Proper aspiration and incremental dosing are recommended to avoid inadvertent intravascular injection.

The most serious risks associated with levobupivacaine include cardiac arrhythmias, severe hypotension, seizures, and methemoglobinemia. These events are rare but can be life‑threatening, especially if large systemic doses are inadvertently administered. Immediate recognition and supportive measures, such as cardiovascular monitoring and seizure control, are essential to mitigate these risks.

Levobupivacaína Altan should be avoided in patients with known hypersensitivity to levobupivacaine or other amide‑type local anesthetics, in individuals with severe cardiac conduction disorders, uncontrolled epilepsy, or significant hepatic impairment that could impair drug metabolism. Caution is also advised in patients receiving other agents that affect cardiac function or sodium channel activity.